Evidence map›Paper›PMID 23454897›Full record

ArticleCell cycle (Georgetown, Tex.)2013

A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Bernard Omolo, Craig Carson, Haitao Chu, Yingchun Zhou, Dennis A Simpson, Jill E Hesse, Richard S Paules, Kristine C Nyhan, Joseph G Ibrahim, William K Kaufmann

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Mechanisms of chromosomal instability in melanoma.Environmental and molecular mutagenesis · 2014
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Bernard OmoloDivision of Mathematics and Computer Science, University of South Carolina Upstate, Spartanburg, SC, USA.
Craig Carson
Haitao Chu
Yingchun Zhou
Dennis A Simpson
Jill E Hesse
Richard S Paules
Kristine C Nyhan
Joseph G Ibrahim
William K Kaufmann
Communities In Schools of Orange County · USNational Institute of Environmental Health Sciences · USUniversity of North Carolina at Chapel Hill · USUniversity of California, San Francisco · USUniversity of Minnesota System · USUniversity of South Carolina Upstate · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
The System of Response to DNA Damage Suppresses Environmental MelanomagenesisP01ES014635 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAUFMANN, WILLIAM K. · 2007 to 2011
$6.7M
Molecular Analysis Of Cell Cycle Control During CarcinogenesisZIAES021157 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI PAULES, RICHARD · 2009 to 2013
$5.1M
Biostatistics for Research in Genomics and CancerT32CA106209 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH G IBRAHIM, Naim Ur Rashid · 2004 to 2026
$4.8M
Intramural NIH HHSNCI NIH HHS CA16086NCI NIH HHS P30 CA016086NCI NIH HHS T32 CA106209NIEHS NIH HHS ES014635NIEHS NIH HHS ES10126NIEHS NIH HHS P01 ES014635NIEHS NIH HHS P30 ES010126
6 · The paper itself

Abstract

As DNA damage checkpoints are barriers to carcinogenesis, G(2) checkpoint function was quantified to test for override of this checkpoint during melanomagenesis. Primary melanocytes displayed an effective G(2) checkpoint response to ionizing radiation (IR)-induced DNA damage. Thirty-seven percent of melanoma cell lines displayed a significant defect in G(2) checkpoint function. Checkpoint function was melanoma subtype-specific with "epithelial-like" melanoma lines, with wild type NRAS and BRAF displaying an effective checkpoint, while lines with mutant NRAS and BRAF displayed defective checkpoint function. Expression of oncogenic B-Raf in a checkpoint-effective melanoma attenuated G(2) checkpoint function significantly but modestly. Other alterations must be needed to produce the severe attenuation of G(2) checkpoint function seen in some BRAF-mutant melanoma lines. Quantitative trait analysis tools identified mRNA species whose expression was correlated with G(2) checkpoint function in the melanoma lines. A 165 gene signature was identified with a high correlation with checkpoint function (p < 0.004) and low false discovery rate (≤ 0.077). The G(2) checkpoint gene signature predicted G(2) checkpoint function with 77-94% accuracy. The signature was enriched in lysosomal genes and contained numerous genes that are associated with regulation of chromatin structure and cell cycle progression. The core machinery of the cell cycle was not altered in checkpoint-defective lines but rather numerous mediators of core machinery function were. When applied to an independent series of primary melanomas, the predictive G(2) checkpoint signature was prognostic of distant metastasis-free survival. These results emphasize the value of expression profiling of primary melanomas for understanding melanoma biology and disease prognosis.

Indexed as

TranscriptomeCell LineDNA DamageG2 Phase Cell Cycle CheckpointsGTP PhosphohydrolasesHumansMelanocytesMelanomaMembrane ProteinsProto-Oncogene Proteins B-rafRadiation, IonizingBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafG2 checkpointionizing radiationmelanomamicroarrayoncogene

Identifiers

PMID23454897
PMCPMC3646863
OpenAlexW2016714017

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.